Literature DB >> 1941541

Percutaneous penetration and skin retention of topically applied compounds: an in vitro-in vivo study.

W G Reifenrath1, G S Hawkins, M S Kurtz.   

Abstract

Radiolabeled compounds with varying partition coefficients (paraoxon, benzoic acid, parathion, and DDT) were chosen to study the percutaneous penetration and extent of dermal retention in pig skin both in vitro and in vivo. Radiolabel distributions within the skin were determined from 1 min to 24 h after application in ethanol. The distribution of radioactivity in the skin during the first 4 h was comparable between in vitro and in vivo experiments. At 24 h, radioactive residues in the dermis were significantly higher in vitro than in vivo for DDT, the most lipophilic compound. Increasing air flow over the skin surface significantly increased evaporative loss for volatile compounds (benzoic acid, N,N-diethyl-m-toluamide, malathion, parathion, and DDT), significantly decreased the residues in the upper skin layer for N,N-diethyl-m-toluamide, malathion, parathion, and DDT, significantly decreased the dermal residue for malathion, and significantly decreased the penetration of N,N-diethyl-m-toluamide, malathion, and parathion. On a percentage basis, increasing the dose of parathion and paraoxon from 4 to 1000 micrograms/cm2 resulted in significantly lower residues in the dermis. When applied to the dermis, the more hydrophilic benzoic acid and paraoxon better penetrated the dermis than the more hydrophobic parathion and DDT. An ethanol vehicle facilitated the penetration of parathion into the dermis and receptor fluid. These results indicate that the dermis interacted with the penetrant during both in vitro and in vivo percutaneous absorption. Factors such as partition coefficient and dose of the penetrant, air flow over the skin, and vehicle changed the distribution of penetrants in the skin and percutaneous penetration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941541     DOI: 10.1002/jps.2600800605

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  A new method to determine the distribution of a fluorophore in scalp skin with focus on hair follicles.

Authors:  Ylva Y Grams; Joke A Bouwstra
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

2.  Interactions of skin thickness and physicochemical properties of test compounds in percutaneous penetration studies.

Authors:  Simon C Wilkinson; Wilfred J M Maas; Jesper Bo Nielsen; Laura C Greaves; Johannes J M van de Sandt; Faith M Williams
Journal:  Int Arch Occup Environ Health       Date:  2006-01-25       Impact factor: 3.015

3.  Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A.

Authors:  Luciana B Lopes; Denise A Ferreira; Daniel de Paula; M Tereza J Garcia; José A Thomazini; Márcia C A Fantini; M Vitória L B Bentley
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

4.  Effects of growth conditions on the barrier properties of a human skin equivalent.

Authors:  Priya Batheja; Yifan Song; Philip Wertz; Bozena Michniak-Kohn
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

5.  Lamellar liquid crystalline phases for cutaneous delivery of Paclitaxel: impact of the monoglyceride.

Authors:  Jaclyn M Hosmer; Alexandre A Steiner; Luciana B Lopes
Journal:  Pharm Res       Date:  2012-11-08       Impact factor: 4.200

6.  Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery.

Authors:  Qi Tan; Weidong Liu; Chenyu Guo; Guangxi Zhai
Journal:  Int J Nanomedicine       Date:  2011-08-10

7.  A 3D-psoriatic skin model for dermatological testing: The impact of culture conditions.

Authors:  Alexandra Duque-Fernandez; Lydia Gauthier; Mélissa Simard; Jessica Jean; Isabelle Gendreau; Alexandre Morin; Jacques Soucy; Michèle Auger; Roxane Pouliot
Journal:  Biochem Biophys Rep       Date:  2016-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.